Atypical ductal hyperplasia of the breast: the controversial management of a borderline lesion: experience of 47 cases diagnosed at vacuum-assisted biopsy.

The present paper describes our experience of 47 cases of atypical ductal hyperplasia (ADH) diagnosed at vacuum-assisted biopsy. From June 1999 to December 2003, 47 consecutive diagnoses of non-palpable ADH of the breast were made by 11-gauge vacuum-assisted biopsy (Mammotome). Of these, 17 were subjected to surgical excision and 11 underwent a second Mammotome at the site of the previous vacuum-assisted biopsy. Diagnostic underestimation occurred in only two cases, with a surgical diagnosis of ductal carcinoma in situ. In both patients, aged between 46 and 55 years, the radiological images showed microcalcifications of >20 mm, and the lesions were not completely removed by Mammotome. Despite the obvious limitations of the present study, it can be concluded that the probability of underestimating ADH diagnosis by Mammotome appears to be related to the radiological features of the lesion (>20 mm) and to the adequacy of specimens.

Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients.

Predicting the survival of terminally ill cancer patients can help in informing patients and their families, in programming therapy and assistance models, and in utilising existing resources correctly. Clinical prediction of survival (CPS) and Karnofsky performance status (KPS) are two factors which have already been described in the literature. The aim of our study was to verify their respective predictive value with regard to actual survival. In our study of 100 consecutive patients, the CPS obtained a higher prediction accuracy than that reported previously (correlation coefficient with actual survival = 0.51) and than that obtained with KPS alone (correlation coefficient = 0.37). The median difference between predicted and expected survival was only 1 week. The resultant predictivity could be further improved by integrating other prognostic factors studied in larger prospective, multicentric studies.

Description of a home care service for cancer patients through quantitative indexes of evaluation.

Home care (HC) was created and developed in Romagna, as in other parts of Italy, thanks to the endeavor of a private institution, the "Istituto Oncologico Romagnolo". The care is gratis to advanced cancer patients and is based on the palliative philosophy of treatment of the symptoms and the person within the framework of continuity of care permitted by the oncologic approach. To evaluate the intensiveness of the operation in terms of medical and nursing care by means of quantitative indexes, we examined several variables which emerged from a retrospective analysis of our case study. The average duration of care of the 484 patients in the program as of 31 December 1990 was 84.1 days. Four hundred and twenty-three patients of the 484 (87.1% of the total) have died and 61 were still in the HC program at the time of this analysis. The 61 living patients were thus excluded from the descriptive analysis to give greater homogeneity to the study group. The average duration of care for the 423 decreased patients was 68.1 days. Out of a total of 28,759 days of HC for the entire group, the patients actually spent 23,534 days (81.8%) at home. The average duration of hospitalization was 13.5 days, and in 33.2% of the cases it was motivated by psychologic and family causes. The place of death was the home in 44.3% of the cases. A medical or nursing visit was made at the home every 1.4 days, and the average number of visits per patient was 39.0. Although none of the indexes alone can give overall indications of the intensiveness of a HC service, they may constitute a working proposal for the definition of the most objective criteria possible for the quantitative evaluation of such experiences.

Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.

The Authors report their experiences on the treatment of 13 consecutive cases of gastro-intestinal carcinoid tumors observed over the last 11 years. The primary sites were as follows: intestine (5 cases), appendix (3 cases), colon (1 case) and peritoneum (4 cases); only 3 patients presented systemic signs. Ten patients in advanced phase were treated with a chemotherapeutic regimen containing 5-fluorouracil (5-Fu) and streptozotocin (STZ). One case was excluded from the study because of a concomitant gastric carcinoma. Of the 9 evaluable patients, two achieved partial remission (22%) with a duration of 18+ and 66 months respectively; 4 (44.5%) had stable disease for periods ranging from 7 to 40 months and 3 cases progressed. Severe toxicity (thrombocytopenia and diarrhea) occurred in 2 cases and disappeared with the suspension of therapy. The systemic signs disappeared with treatment and did not appear in 2 cases out of 3. The prospective of the employment of new drugs such as alpha-interferon and, above all, somatostatin provides hope that this uncommon disease may have an improved response rate to treatment in the future.